CentraleSupélec

CentraleSupélec strives for becoming a worldwide recognized teaching institution. To achieve this goal, it relies on excellence in basic science and applied sciences such as maths, physics, IT, engineer sciences, energetics, process, mechanics and industrial engineering.

Research

Research Published on 03/01/2022

Congratulations to Jean-Christophe Pesquet, director of the Centre fo Visual Computing (CVN) laboratory: He has just been named "EURASIP Fellow 2022". This is an extremely prestigious title, only 3 people have obtained it in Europe in 2022.

EURASIP stands for "The European Association for Signal Processing". It was founded in 1978 with the aim/objective of improving communication between groups and individuals working in the multidisciplinary field of signal processing in Europe and elsewhere, of exchanging and disseminating information in the field of signal processing, and of furthering the efforts of researchers by providing a scholarly and professional platform for the dissemination and discussion of all aspects of signal processing, without seeking to generate profit or any other material benefit.

The CVN laboratory, associated with INRIA Saclay, is situated at the intersection of mathematics and computer science, in search of mathematical models and their computational solutions for the automatic structuring, interpretation and understanding of massive (visual) data with a focus on machine learning, computer vision and discrete models in biomedical image analysis.

 

 

 

 

 

Research Published on 01/18/2022

'Scientific excellence alone will not be enough to turn the tide or at least influence it. Nor is it simply a matter of being a better communicator. It is probably more a question of acting to induce a change of posture or paradigm in your interlocutors and stakeholders. Nudge, social marketing, risk management... These are all areas that will undoubtedly need to be invested in to move in this direction.'

Professor Pascal Morenton has just created "Look Up" (in reference to the current film): a multidisciplinary working group whose objective is to provide any scientist or engineer who wishes to do so with a conceptual and methodological framework as well as techniques and tools to better communicate, convince and finally have a real influence on decisions or major orientations related to global or systemic issues.

Any contribution to enrich the current reflection will be welcome, do not hesitate to contact him to talk about it.

 

Research Published on 10/21/2021

CNRS, the Paris Polytechnic Institute and the University of Paris-Saclay met on the CNRS campus in Gif-sur-Yvette to renew the partnerships between the national research organization and the two academic clusters on the Saclay plateau for the period 2020-2025. The presidents and directors of the CNRS, the Institut Polytechnique de Paris with the École Polytechnique, ENSTA Paris, and GENES, and the Université Paris-Saclay with AgroParisTech, CentraleSupélec, the Ecole Normale Supérieure Paris-Saclay, and the Institut d'Optique Graduate School, all share a common ambition to strengthen fundamental research, increase the potential for innovation, and enhance the region's international attractiveness.

 

 

Research Published on 10/14/2021

Congratulations to researcher Sébastien Ducruix, head of EM2C laboratory (with CNRS) who has been appointed as Associated Fellow by American Institute of Aeronautics and Astronautics (AIAA).

'Congratulations to each member of the Class of 2022 Associate Fellows,” said AIAA President Basil Hassan. “This distinguished group of individuals exemplify passion and dedication to advancing the aerospace profession. Each of them was selected because of their significant and lasting contributions to the field. They are truly shaping the future of aerospace.'

 

The grade of Associate Fellow recognizes individuals “who have accomplished or been in charge of important engineering or scientific work, or who have done original work of outstanding merit, or who have otherwise made outstanding contributions to the arts, sciences, or technology of aeronautics or astronautics.” To be selected as an Associate Fellow an individual must be an AIAA Senior Member in good standing, with at least 12 years of professional experience, and be recommended by three current Associate Fellows.

 

“The AIAA Associate Fellows personify the innovation that drives our industry forward,” said Dan Dumbacher, AIAA executive director. “The members of the Class of 2022 Associate Fellows embody the commitment, dedication, and ingenuity that are crucial for devising the best solutions to the complex questions raised across the aerospace community. On behalf of the Institute, we recognize the families, friends, and colleagues who support the Associate Fellows as they contribute in such a meaningful way to the aerospace community.”

 

 

 

 

 

Research Published on 10/06/2021

PhD student Jeanne Redaud, laboratory of signals and systems (L2S) has just won IFAC Student Best Paper Award at 6th IFAC Workshop on Time-Delay Systems. This event has been held in China and is considered as THE conference in Time Delay Systems experts.

This is the second time that a PhD student of L2S is awarded this prize. Last time, it was Bogdan LIACU at 10th IFAC Workshop on Time-Delay Systems which was held in Boston in 2012.

Research Published on 09/16/2021

Sanofi, Capgemini, Ypso-Facto, GPC Bio, CEA, and CentraleSupélec announce the launch of the project CALIPSO (Capteurs en Ligne de Procédés et Solutions Innovantes en Bioproduction, or Online Process Sensors and Innovative Bioproduction Solutions).

This project, with a total budget of nearly €17.5M, is publicly backed to the tune of €M 8.059 as part of the PSPC n°9 call to tender, operated on behalf of the State by Bpifrance through the Future Investment Program (PIA). The objective of the CALIPSO project is to develop a new generation of tools that will revolutionize R&D methodology and the management of industrial bioproduction processes, thus enabling productivity gains up to a factor 10.  

Biomedicines constitute a range of innovative medicines, which have the distinctive feature of relying on extractions from living biological organisms for the production of their active ingredients. Biomedicines currently represent 40% of medicines under development, thus giving them a crucial role in the therapeutic arsenal available to healthcare professionals. These innovative therapies pave the way for the emergence of new generations of vaccines and treatments for diseases which are currently incurable with medicines based on synthetic chemical active ingredients.

While France is a latecomer regarding the production of biomedicines and is dependent on imports for medical equipment, active ingredients and medicines, actors in the bioproduction sector are mobilizing to boost French production capacities to adapt to market demands. This collective effort is necessary to enhance productivity, accelerate access to new medicines at an acceptable cost as well as to ensure France’s competitiveness and its health independence. It is a strategic issue that has been identified by the Comité Stratégique de Filière-Industrie et Technologies de Santé (Strategic Committee for the Healthcare Technology and Industrial Sector).

A new paradigm for bioproduction processes

The objective of the CALIPSO project is to offer a new approach to manage bioproduction processes, by developing cutting-edge technologies along with IT solutions that enable their exploitation. The use of digital tools and solutions on bioproduction development lines will increase productivity whilst ensuring the production of very high-quality batches.

The project will lay down the groundwork towards more flexible and automated production solutions, a key step to accompany the transformation and personalization of medical care.

The CALIPSO project is articulated around three major ambitions:

  • The development and transfer of technologies to the pre-industrialization of a new generation of micro-sensors which will enable to solve problems for which there are currently no efficient solutions at the global level.
     
  • The implementation of a new approach to model bioproduction processes, by using pre-existing data alongside data generated by new sensors. Ultimately, the sector aims to conceive databases designed in a way that integrates and stocks all data.  This data will enable the creation of identical digital representations (“digital twins”) and processes which will in turn facilitate prediction tools to optimize certain steps of the purification process. In addition, real-time regulation systems could also be used throughout the various steps of cell cultivation.
     
  • The simultaneous exploitation of all this data (thousands per batch), piloted by artificial intelligence, will accelerate molecule selection and their large-scale production in record time.

An innovative and unique project dedicated to competitive biotherapies

The consortium aims, via CALIPSO, to have a major positive impact on public health: on the one hand, the development of French bioproduction should lessen the strain caused by the cost of certain medicines on the French healthcare system by proposing alternatives that are accessible to the biggest number. On the other hand, the project will allow significant timesaving when it comes to bioproducing new cures and vaccines.

This acceleration will therefore offer new solutions and better care for certain pathologies such as cancer or auto-immune diseases. Furthermore, the different technological innovations developed within the CALIPSO framework will enable the conception of completely automated miniature systems for more personalized care. These new tools will increase the production capacity of specific treatments that are adapted to specific sub-segments of the population or even tailor-made for individual patients, by making production more reactive, more agile, faster and cheaper.

Dr. Jacques Volckmann, President of the CSF-ITS Bioproduction steering committee, VP R&D Sanofi France declared: “This novel project unites the best public and private-sector experts in France to build a broad and innovative project in the development of French bioproduction capacity, a key issue for the sector. Sanofi, a leader in the healthcare sector and in biomedical research, will drive the project alongside all other parties involved.”

Mr. Jean-François Toussaint, Global Head of Research & Development, Sanofi Pasteur declared: "The CALIPSO project represents a tremendous opportunity to accelerate the development of biomanufacturing processes by capturing and using more data. This will allow us to identify and control critical process parameters and to transfer them to industrial scale more rapidly. Patients will be the primary beneficiaries of this project as they will have faster access to therapeutic innovations from our R&D portfolio, which are more than 60% biologics and vaccines.”

David Chovaux, VP | Deputy Managing Director of Capgemini Engineering declared: “As integrators of technological and digital solutions, we have been committed for many years alongside major healthcare actors to contribute to this smart industry consortium and to empower the next generation of healthcare treatments.  Evaluating technologies likely to improve the efficiency of bioproduction thanks to smart sensors, real-time data and artificial intelligence is a crucial issue for the future.”

Mrs. Agnès Corbin, Business Development Manager, Ypso-Facto, declared: “Ypso-Facto is proud of its contribution to tackling the challenges relating to bioproduction in France, especially those pertaining to productivity and competitiveness. Alongside Sanofi and other renowned partners, our expertise in modelling and our predictive capabilities will serve as a lever to develop innovative therapies in future.”

Mr. Zsolt Popse, CEO GPC Bio, declared: “The team at GPC Bio is very happy to actively participate in the development of this new process and of bioproduction sensors, linking artificial intelligence and hi-tech. Along with Sanofi and our partners, our knowledge and expertise as bioproduction equipment manufacturers will actively contribute to the launch of a new generation of industrial equipment.”

Mrs. Nadège Nief, Deputy Head Micro-Technologies for Biology and Healthcare Division at CEA declared: “The Calipso project is an extraordinary opportunity to develop sensors and innovative systems to optimize bioproduction yiets. The CEA is proud to be a part of it and will bring its know-how in conceiving, developing, and integrating cutting-edge sensors to better monitor in and at-line USPs (Upstream Processes) and DSPs (Downstream Processes) phases.  Regarding industrial transfers, we aim to contribute to the creation or the strengthening of a French or European sensor manufacturer and to supplement GPC bio’s offer, which will integrate these ground-breaking technologies in its bioproduction equipment.”

Prof. Patrick Perré, Head of the Biotechnology Chair, Engineering of Processes and Materials Laboratory, CentraleSupélec declared: “Relying on CentraleSupélec’s core skills, the Biotechnology chair has structured its project around the concepts of a “digital twin” and of instrumentation. We are delighted to place our know-how and that of the Metz campus, in collaboration with a high-level consortium, at the service of an ambitious project in a key sector for France, from both an economic and a strategic standpoint.

Clémentine Lamarre, Healthcare Manager at Bpifrance’s Innovation Directorate, commented: “We are happy to accompany Sanofi and its partners in the development of new tools to analyse and monitor bioproduction. This project deals with the challenges of “Biotherapies and bioproduction of innovative therapies”, announced by the government in January 2021, amongst other acceleration strategies identified within the framework of PIA4. It should enable the optimisation of quality, costs, and timeframes for biomedicine production, which constitute a decisive opportunity for patients and currently represents over 50% of ongoing clinical trials.”

The socioeconomic impact of the CALIPSO project on the bioproduction stream  

The CALIPSO project will have a broad socioeconomic impact on the entire bioproduction stream. In the short-term, it will enable the creation of 100 jobs across various fields. Furthermore, it will have a positive impact on the entire value chain with the creation of R&D jobs in both big corporations and SMEs, with specific know-how relating to the development of sensors and artificial intelligence at their core.

In addition, CALIPSO will yield a cumulative turnover estimated at €250M by 2035, for its tools and the solutions it would have developed. It will play an important role in maintaining investments in the French pharmaceutical sector and will place the country at the heart of their bioproduction strategies.

 

About CALIPSO

CALIPSO is a research & development (R&D) PSPC (Structuring Project for Competitiveness) for French medical research which will be conducted over the next 5 years. Operated by Bpifrance within the framework of the Programme d’Investissements d’Avenir (PIA, or Future Investments Programmes), the objective of PSPCs is to structure various industrial sectors and help new ones emerge, thanks to the collaboration of private-sector and academic partners around ambitious projects. 

Financed by public and private funds and coordinated by Sanofi, the CALIPSO project unites technological expertise, industrial actors and leading participants:

  • Sanofi will bring its widespread expertise in biopharmaceutical production (vaccinations or biotherapies)
  • Capgemini Engineering, relying on the engineering and R&D capabilities of the Capgemini Group, will bring its expertise in transforming data into knowledge to stimulate and optimise complex processes thanks to artificial intelligence.
  • Ypso-Facto will bring its expertise in developing tools to enable the visualisation of data in a structured, interactive and flexible manner, as well as in predictive software for the development and the optimisation of bioreactors (USP) and purifications (DSP).
  • Global Process Concept will bring its technical expertise and tools in matters of modelling, retroactive monitoring and prediction.
  • The CEA brings its technological expertise by developing a new generation of sensors, enabling the implementation of monitoring and decision-making systems.
  • CentraleSupélec will bring its academic expertise in modelling and bioprocesses simulation

 

 

 

 

 

 

 

Research Published on 04/12/2021

A team of researchers from the Mechanics of Soils, Structures and Materials laboratory (UMR 8579 with CNRS) has just created a numerical simulation of an earthquake in the Cadarache region in southwestern France for a strong ground motion scenario Mw6.0.

See video below:

 

Code: SEM3D (Ver 2017.04 Registered at French Agency for Protection of Programs (Dépôt APP), 2017).
Simulation performed @Occigen (CINES allocation 2020-A0080410444) on 2000 MPI processes.

Contact: David Castro-Cruz (david.castro-cruz@centralesupelec.fr), research engineer in Computational Earthquake Engineering

 

 

 

Research Published on 04/02/2021

Researchers from CentraleSupélec's Photonics Chair have participated in the creation of a laser that generates more than 250 trillion random numbers per second, used to secure digital information. This project was carried out within an international collaboration (LMOPS laboratory of CentraleSupélec and the University of Lorraine, Yale University, Trinity College Dublin, Imperial College London and Nanyang University of Technology in Singapore).

Every second, several tens of billions of digital data circulate in each of our telecommunication links. To secure this information, a random data generation system is used. Current techniques include algorithms that generate these numbers, as well as physical noise sources, often of electronic or thermal origin. However, both techniques have their limitations: the first is vulnerable to software intrusions and the second has a limited throughput.

This record is more than 1,000 times greater than the 2014 record, also set by the Photonics Chair, since it allows the generation of 250 billion billion numbers.

Research Published on 03/29/2021

The International Council on Systems Engineering (INCOSE) is a not-for-profit membership organization founded to develop and disseminate the interdisciplinary principles and practices that enable the realization of successful systems. INCOSE is designed to connect SE professionals with educational, networking, and career-advancement opportunities in the interest of developing the global community of systems engineers and systems approaches to problems. We are also focused on producing state-of-the-art work products that support and enhance this discipline’s visibility in the world.

Professor Guy André Boy, holder of the FlexTech chair dedicated to human-systems integration in increasingly autonomous complex systems (LGI laboratory/CentraleSupélec, ESTIA), has just been named Fellow of INCOSE. He is thus recognized as an exceptional contributor in the field (among 80 worldwide and the 2nd in France).

INCOSE Fellows are individuals with significant verifiable contributions to the art and practice of Systems Engineering in industry, government or academia. This award recognizes practitioners from government and industry applying knowledge and contributing to the practice of systems engineering in designing and acquiring systems, researchers developing new knowledge, pushing the theory forward, and teachers disseminating knowledge and developing the next generation of successful systems engineers.

 

 

 

Research Published on 11/03/2020

Application-Driven Quantum and Statistical Physics
A Short Course for Future Scientists and Engineers
Volume 3: Transitions

Bridging the gap between traditional books on quantum and statistical physics, this series is an ideal introductory course for students who are looking for an alternative approach to the traditional academic treatment. By professor Jean-Michel Gillet (CentraleSupélec, Paris-Saclay University, France & Centrale Pékin, Beihang University, China)

This pedagogical approach relies heavily on scientific or technological applications from a wide range of fields. For every new concept introduced, an application is given to connect the theoretical results to a real-life situation. Each volume features in-text exercises and detailed solutions, with easy-to-understand applications.

This third volume covers several basic and more advanced subjects about transitions in quantum and statistical physics. Part I describes how the quantum statistics of fermions and bosons differ and under what condition they can merge into the classical-particle-statistics framework seen in Volume 2. This section also describes the fundamentals of conductors, semiconductors, superconductors, superfluids and Bose–Einstein condensates. Part II introduces time-dependent transitions between quantum states. The time evolution of a simple two-level model gives the minimum background necessary to understand the principles behind lasers and their numerous applications. Time-dependent perturbation theory is also covered, as well as standard approaches to the scattering of massive particles. A semi-classical treatment of electromagnetic field–matter interaction is described with illustrations taken from a variety of processes such as phonon scattering, charge distribution or spin densities. The third and last part of the book gives a brief overview of quantum electrodynamics with applications to photon absorption or emission spectroscopies and a range of scattering regimes. There follows a short introduction to the role of multiphoton processes in quantum entanglement based experiments.

 

Pages